An MT1-MMP-PDGF receptor-β axis regulates mural cell investment of the microvasculature

  1. Kaisa Lehti1,3,
  2. Edward Allen1,
  3. Henning Birkedal-Hansen2,
  4. Kenn Holmbeck2,
  5. Yasuhiro Miyake1,
  6. Tae-Hwa Chun1, and
  7. Stephen J. Weiss1,4
  1. 1Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA; 2National Institute of Dental and Craniofacial Research, Bethesda, Maryland 20892, USA

Abstract

Platelet-derived growth factor (PDGF)/PDGFRβ-dependent investment of the vascular endothelium by mural cells (i.e., pericytes and vascular smooth muscle cells; VSMCs) is critical for normal vessel wall structure and function. In the developing vasculature, mural cell recruitment is associated with the functionally undefined expression of the type I transmembrane proteinase, membrane-type 1 matrix metalloproteinase (MT1-MMP). In this paper, using VSMCs and tissues isolated from gene-targeted mice, we identify MT1-MMP as a PDGF-B-selective regulator of PDGFRβ-dependent signal transduction and mural cell function. In VSMCs, catalytically active MT1-MMP associates with PDGFRβ in membrane complexes that support the efficient induction of mitogenic signaling by PDGF-B in a matrix metalloproteinase inhibitor-sensitive fashion. In contrast, MT1-MMP-deficient VSMCs display PDGF-B-selective defects in chemotaxis and proliferation as well as ERK1/2 and Akt activation that can be rescued in tandem fashion following retroviral transduction with the wild-type protease. Consistent with these in vitro findings, MT1-MMP-deficient brain tissues display a marked reduction in mural cell density as well as abnormal vessel wall morphology similar to that reported in mice expressing PDGF-B or PDGFRβ hypomorphic alleles. Together, these data identify MT1-MMP as a novel proteolytic modifier of PDGF-B/PDGFRβ signal transduction that cooperatively regulates vessel wall architecture in vivo.

Keywords

Footnotes

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1294605.

  • 3 Current address: Departments of Virology and Pathology, Haartman Institute and Biomedicum Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, FIN-00014, Finland.

  • 4 Corresponding author. E-MAIL sjweiss{at}umich.edu; FAX (734) 647-7950.

    • Accepted March 2, 2005.
    • Received December 30, 2004.
| Table of Contents

Life Science Alliance